ArticleAdvances in therapy2026
The Impact of Diabetes on Risk of Revision Following Anterior Cruciate Ligament Reconstruction: A Real-World Data Study.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionGiven the increasing prevalence of diabetes mellitus (DM), understanding its impact on anterior cruciate ligament reconstruction (ACLR) revision risk is important for clinical decision-making and patient counselling. This study evaluated whether DM is associated with an increased risk of revision ACLR within 5 years of primary reconstruction.
methodsWe conducted a retrospective observational cohort study using a global federated health research network (TriNetX, Cambridge, USA), including 73,951 patients who underwent primary ACLR across 53 healthcare organisations, of whom 990 had DM (type 1 and 2). Patients undergoing primary ACLR between 5 August 2005 and 4 August 2025 were included. The index event was primary ACLR, and the outcome was subsequent ACLR to the ipsilateral knee. Follow-up was extended until revision surgery or up to 5 years. Patients with DM (type 1 or type 2) were compared with patients without DM following 1:1 propensity score matching for age, sex, and BMI. Following propensity score matching, 988 patients were analysed per cohort. Kaplan-Meier survival analysis and hazard ratios (HRs) were used to assess revision risk. A further sensitivity analysis excluded patients undergoing concomitant soft tissue knee procedures, including meniscectomy, meniscal repair, meniscal transplantation, and additional ligament reconstruction procedures.
resultsOf the 73,951 patients included, 990 had DM, corresponding to a prevalence of 1.3% among individuals undergoing ACLR. Following propensity score matching, revision ACLR occurred in 30 of 988 patients with DM and 38 of 988 patients without DM, with no statistically significant difference in revision risk between the cohorts (HR 0.77, 95% CI 0.47-1.26). In the sensitivity analysis excluding patients with concomitant soft tissue knee procedures, between 1 and 10 revision events occurred in each matched cohort (243 patients per cohort), and no statistically significant difference in revision risk was observed (HR 0.45, 95% CI 0.08-2.45).
conclusionDM was not associated with an increased risk of revision ACLR within 5 years of the primary procedure. These findings were consistent in a sensitivity analysis excluding concomitant soft tissue knee procedures. The results should be interpreted in the context of the study's limitations and do not replace individualised clinical risk assessment.
Indexed as
Identifiers
42886432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.